Polyphenols as Wnt/β-catenin pathway modulators: A promising strategy in clinical neurodegeneration

Abstract

Polyphenols, a diverse group of naturally occurring compounds found in plants, have garnered significant attention for their potential therapeutic properties in treating neurodegenerative diseases (NDs). The Wnt/β-catenin (WβC) signaling pathway, a crucial player in neurogenesis, neuronal survival, and synaptic plasticity, is involved in several cellular mechanisms related to NDs. Dysregulation of this pathway is a hallmark in the development of various NDs. This study explores multiple polyphenolic compounds, such as flavonoids, stilbenes, lignans, and phenolic acids, and their potential to protect the nervous system. It provides a comprehensive analysis of their effects on the WβC pathway, elucidating their modes of action. The study highlights the dual function of polyphenols in regulating and protecting the nervous system, providing reassurance about the research benefits. This review provides a comprehensive analysis of the results obtained from both in vitro studies and in vivo research, shedding light on how these substances influence the various components of the pathway. The focus is mainly on the molecular mechanisms that allow polyphenols to reduce oxidative stress, inflammation, and apoptotic processes, ultimately improving the function and survival of neurons. This study aims to offer a thorough understanding of the potential of polyphenols in targeting the WβC signaling pathway, which could lead to the development of innovative therapeutic options for NDs.

Keywords

neurodegenerative diseases / neurological diseases / polyphenols / Wnt/β-catenin pathway

References

[1] Borsook D. Neurological diseases and pain. Brain. 2012;135(2):320-344.

[2] Momin EN, Mohyeldin A, Zaidi HA, Vela G, Quiñones-Hinojosa A. Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Curr Stem Cell Res Ther. 2010;5(4):326-344.

[3] Leinenga G, Langton C, Nisbet R, Götz J. Ultrasound treatment of neurological diseases-current and emerging applications. Nat Rev Neurol. 2016;12(3):161-174.

[4] Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(7):1139-1151.

[5] Kumar GP, Anilakumar KR, Naveen S. Phytochemicals having neuroprotective properties from dietary sources and medicinal herbs. Pharm J. 2015;7(1):1-17. doi:10.5530/pj.2015.7.1

[6] Saxena S. Role of medicinal plants in neurodegenerative diseases. J Int Med Sci Acad. 2015;28(4):218-221. doi:10.1007/s40898-017-0004-7

[7] Gao J, Liao Y, Qiu M, Shen W. Wnt/β-catenin signaling in neural stem cell homeostasis and neurological diseases. Neuroscientist. 2021;27(1):58-72.

[8] Mo Z, Zeng Z, Liu Y, Zeng L, Fang J, Ma Y. Activation of Wnt/Beta-catenin signaling pathway as a promising therapeutic candidate for cerebral ischemia/reperfusion injury. Front Pharmacol. 2022;13:914537.

[9] Huang P, Yan R, Zhang X, Wang L, Ke X, Qu Y. Activating Wnt/β-catenin signaling pathway for disease therapy: challenges and opportunities. Pharmacol Ther. 2019;196:79-90.

[10] Vallée A, Vallée JN, Lecarpentier Y. Parkinson’s disease: potential actions of lithium by targeting the WNT/Β-catenin pathway, oxidative stress, inflammation and glutamatergic pathway. Cells. 2021;10(2):1-16.

[11] Lengfeld JE, Lutz SE, Smith JR, et al. Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis. Proc Natl Acad Sci USA. 2017;114(7):E1168-E1177.

[12] Libro R, Bramanti P, Mazzon E. The role of the Wnt canonical signaling in neurodegenerative diseases. Life Sci. 2016;158:78-88.

[13] Ramakrishna K, Nalla LV, Naresh D, et al. WNT-β catenin signaling as a potential therapeutic target for neurodegenerative diseases: current status and future perspective. Diseases. 2023;11(3):89.

[14] Das R, Mitra S, Tareq AM, et al. Medicinal plants used against hepatic disorders in Bangladesh: a comprehensive review. J Ethnopharmacol. 2022;282:114588.

[15] Petlevski R, Hadžija M, Slijepčevič M, Juretič D. Effect of “antidiabetis” herbal preparation on serum glucose and fructosamine in NOD mice. J Ethnopharmacol. 2001;75(2–3):181-184.

[16] Bhullar KS, Rupasinghe HPV. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev. 2013;2013:1-18.

[17] Shi R, Gao D, Stoika R, Liu K, Sik A, Jin M. Potential implications of polyphenolic compounds in neurodegenerative diseases. Crit Rev Food Sci Nutr. 2022;64:5491-5514.

[18] Moradi SZ, Jalili F, Farhadian N, et al. Polyphenols and neurodegenerative diseases: focus on neuronal regeneration. Crit Rev Food Sci Nutr. 2022;62(13):3421-3436.

[19] Fukutomi R, Ohishi T, Koyama Y, Pervin M, Nakamura Y, Isemura M. Beneficial effects of epigallocatechin-3-o-gallate, chlorogenic acid, resveratrol, and curcumin on neurodegenerative diseases. Molecules. 2021;26(2):415.

[20] Maleki Dana P, Sadoughi F, Mansournia MA, Mirzaei H, Asemi Z, Yousefi B. Targeting Wnt signaling pathway by polyphenols: implication for aging and age-related diseases. Biogerontology. 2021;22(5):479-494.

[21] Theodosis-Nobelos P, Rekka EA. The multiple sclerosis modulatory potential of natural multi-targeting antioxidants. Molecules. 2022;27(23):8402.

[22] Akter R, Rahman H, Behl T, et al. Prospective role of polyphenolic compounds in the treatment of neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2021;20(5):430-450.

[23] Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics. 2013;5(3):457-471.

[24] El Gharras H. Polyphenols: food sources, properties and applications—a review. Int J Food Sci Technol. 2009;44(12):2512-2518.

[25] Kabera JN, Semana E, Mussa AR, He X. Plant secondary metabolites: biosynthesis, classification, function and pharmacological properties. J Pharm Pharmacol. 2014;2:377-392.

[26] Corcoran MP, McKay DL, Blumberg JB. Flavonoid basics: chemistry, sources, mechanisms of action, and safety. J Nutr Gerontol Geriatr. 2012;31(3):176-189.

[27] Kelly EH, Dennis JB, Anthony RT. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem. 2002;13:572-584.

[28] Tsao R, Mccallum J. Chemistry of flavonoids. In: de la Rosa LA, Alvarez-Parrilla E, González-Aguilar GA, eds. Fruit and Vegetable Phytochemicals: Chemistry, Nutritional Value, and Stability. John Wiley & Sons, Ltd; 2009:131-153.

[29] Shashank K, Abhay KP. Chemistry and biological activities of flavonoids: an overview. Sci World J. 2013;58(4):145-148.

[30] Jia X, Yang D, Xie H, Jiang Y, Wei X. Non-flavonoid phenolics from Averrhoa carambola fresh fruit. J Funct Foods. 2017;32:419-425.

[31] Chou YC, Ho CT, Pan MH. Stilbenes: chemistry and molecular mechanisms of anti-obesity. Curr Pharmacol Rep. 2018;4(3):202-209.

[32] Pecyna P, Wargula J, Murias M, Kucinska M. More than resveratrol: new insights into stilbene-based compounds. Biomol Ther. 2020;10(8):1-40.

[33] Singh M, Kaur M, Silakari O. Flavones: an important scaffold for medicinal chemistry. Eur J Med Chem. 2014;84:206-239.

[34] Leonte D, Ungureanu D, Zaharia V. Flavones and related compounds: synthesis and biological activity. Molecules. 2023;28(18):6528.

[35] Khan MK, Rakotomanomana N, Loonis M, Dangles O. Chemical synthesis of citrus flavanone glucuronides. J Agric Food Chem. 2010;58(14):8437-8443.

[36] Luo Y, Jian Y, Liu Y, Jiang S, Muhammad D, Wang W. Flavanols from nature: a phytochemistry and biological activity review. Molecules. 2022;27(3):719.

[37] Andrés-Lacueva C, Medina-Remon A, Llorach R, et al. Phenolic compounds: chemistry and occurrence in fruits and vegetables. In: de la Rosa LA, Alvarez-Parrilla E, González-Aguilar GA, eds. Fruit and Vegetable Phytochemicals: Chemistry, Nutritional Value, and Stability. John Wiley & Sons, Ltd; 2009:53-88.

[38] Tsao R, Yang R, Young JC, Zhu H. Polyphenolic profiles in eight apple cultivars using high-performance liquid chromatography (HPLC). J Agric Food Chem. 2003;51(21):6347-6353.

[39] Mendoza-Wilson AM, Glossman-Mitnik D. Theoretical study of the molecular properties and chemical reactivity of (+)-catechin and (−)-epicatechin related to their antioxidant ability. J Mol Struct Theo Chem. 2006;761(1–3):97-106.

[40] Si W, Gong J, Tsao R, Kalab M, Yang R, Yin Y. Bioassay-guided purification and identification of antimicrobial components in Chinese green tea extract. J Chromatogr A. 2006;1125(2):204-210.

[41] Jordheim M. Basic anthocyanin chemistry and dietary sources. Anthocyanins Heal Dis. 2013;1:13-90.

[42] Smeriglio A, Barreca D, Bellocco E, Trombetta D. Chemistry, pharmacology and health benefits of Anthocyanins. Phyther Res. 2016;30:1265-1286.

[43] Andersen ØM, Jordheim M. The anthocyanins. Flavonoids: Chemistry, Biochemistry and Applications. CRC Press; 2006.

[44] McCallum JL, Yang R, Young JC, Strommer JN, Tsao R. Improved high performance liquid chromatographic separation of anthocyanin compounds from grapes using a novel mixed-mode ion-exchange reversed-phase column. J Chromatogr A. 2007;1148(1):38-45.

[45] Negi JS, Bisht VK, Singh P, Rawat MSM, Joshi GP. Naturally occurring Xanthones: chemistry and biology. J Appl Chem. 2013;2013:1-9.

[46] Li G, Thomas S, Johnson JJ. Polyphenols from the mangosteen (Garcinia mangostana) fruit for breast and prostate cancer. Front Pharmacol. 2013;4:80.

[47] Orozco FG, Failla ML. Biological activities and bioavailability of Mangosteen Xanthones: A critical review of the current evidence. Nutrients. 2013;5:3163-3183.

[48] Miranda J, Lasa A, Aguirre L, Fernandez-Quintela A, Milton I, Portillo MP. Potential application of non-flavonoid phenolics in diabetes: Antiinflammatory effects. Curr Med Chem. 2015;22(1):112-131.

[49] Franciosoa A, Mastromarino P, Masci A, d’Erme M, Mosca L. Chemistry, stability and bioavailability of resveratrol. Med Chem (Los Angeles). 2014;10(3):237-245.

[50] Bairwa K, Grover J, Kania M, Jachak SM. Recent developments in chemistry and biology of curcumin analogues. RSC Adv. 2014;4(27):13946-13978.

[51] Jitoe-Masuda A, Fujimoto A, Masuda T. Curcumin: from chemistry to chemistry-based functions. Curr Pharm Des. 2013;19(11):2084-2092.

[52] Esatbeyoglu T, Huebbe P, Ernst IMA, Chin D, Wagner AE, Rimbach G. Curcumin-from molecule to biological function. Angew Chem Int Ed. 2012;51(22):5308-5332.

[53] Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28(12):1937-1955.

[54] Indira PK. Chemical and structural features influencing the biological activity of curcumin. Curr Pharm Des. 2013;19(11):2093-2100.

[55] Priyadarsini KI. Photophysics, photochemistry and photobiology of curcumin: studies from organic solutions, bio-mimetics and living cells. J Photochem Photobiol C: Photochem Rev. 2009;10(2):81-95.

[56] van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development. 2009;136(19):3205-3214.

[57] Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192-1205.

[58] Ferrari GVD, Kaykas A, Kohn AD, Moon RT. WNT and [beta]-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5(9):691-708.

[59] Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985-999.

[60] Berwick DC, Harvey K. The importance of Wnt signalling for neurodegeneration in Parkinson’s disease. Biochem Soc Trans. 2012;40(5):1123-1128.

[61] Serafino A, Sferrazza G, Colini Baldeschi A, et al. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases. Expert Opin Drug Discov. 2017;12(2):169-186.

[62] Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751-764.

[63] Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev. 2006;20(11):1394-1404.

[64] Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13(12):767-779.

[65] Harrison-Uy SJ, Pleasure SJ. Wnt signaling and forebrain development. Cold Spring Harb Perspect Biol. 2012;4(7):1-11.

[66] Bin JY, Gao Q, Tan XX, et al. Lithium alleviates blood-brain barrier breakdown after cerebral ischemia and reperfusion by upregulating endothelial Wnt/β-catenin signaling in mice. Neuropharmacology. 2021;186:186.

[67] Arenas E. Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson’s disease. J Mol Cell Biol. 2014;6:42-53.

[68] Marchetti B. Wnt/β-catenin signaling pathway governs a full program for dopaminergic neuron survival, neurorescue and regeneration in the MPTP mouse model of Parkinson’s disease. Int J Mol Sci. 2018;19(12):3743.

[69] Salinas PC. Wnt signaling in the vertebrate central nervous system: from axon guidance to synaptic function. Cold Spring Harb Perspect Biol. 2012;4(2):a008003.

[70] Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S. Mutant huntingtin-impaired degradation of β-catenin causes neurotoxicity in Huntington’s disease. EMBO J. 2010;29(14):2433-2445.

[71] Jia L, Piña-Crespo J, Li Y. Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease. Mol Brain. 2019;12(1):104.

[72] Anand AA, Khan M, Monica V, Kar D. The molecular basis of Wnt/β-catenin signaling pathways in neurodegenerative diseases. Int J Cell Biol. 2023;2023.

[73] McLeod F, Salinas PC. Wnt proteins as modulators of synaptic plasticity. Curr Opin Neurobiol. 2018;53:90-95.

[74] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.

[75] Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312-339.

[76] Futch HS, Croft CL, Truong VQ, Krause EG, Golde TE. Targeting psychologic stress signaling pathways in Alzheimer’s disease. Mol Neurodegener. 2017;12(1):49.

[77] Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer’s disease. J Mol Cell Biol. 2014;6(1):64-74.

[78] De Ferrari GV, Chacón MA, Barría MI, et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol Psychiatry. 2003;8(2):195-208.

[79] Rosi MC, Luccarini I, Grossi C, et al. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem. 2010;112(6):1539-1551.

[80] Purro SA, Dickins EM, Salinas PC. The secreted Wnt antagonist dickkopf-1 is required for amyloid β-mediated synaptic loss. J Neurosci. 2012;32(10):3492-3498.

[81] Kuwabara T, Hsieh J, Muotri A, et al. Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. Nat Neurosci. 2009;12(9):1097-1105.

[82] Bertram L, Tanzi RE. Genomic mechanisms in Alzheimer’s disease. Brain Pathology. 2020;130(5):966-967.

[83] Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem. 2008;104(6):1433-1439.

[84] Hernández F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J Neurochem. 2002;83(6):1529-1533.

[85] Li HL, Wang HH, Liu SJ, et al. Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin, a mechanism involved in Alzheimer’s nerodegeneration. Proc Natl Acad Sci USA. 2007;104(9):3591-3596.

[86] Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes β-amyloid toxicity in rat hippocampal neurons. Exp Cell Res. 2004;297(1):186-196.

[87] Chacón MA, Varela-Nallar L, Inestrosa NC. Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Aβ oligomers. J Cell Physiol. 2008;217(1):215-227.

[88] Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer’s disease. Mol Psychiatry. 2010;15(3):272-285.

[89] Inestrosa NC, Montecinos-Oliva C, Fuenzalida M. Wnt signaling: Role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol. 2012;7(4):788-807.

[90] Wang JY, Wang X, Wang XJ, et al. Curcumin inhibits the growth via Wnt/γ-catenin pathway in non-small-cell lung cancer cells. Eur Rev Med Pharmacol Sci. 2018;22(21):7492-7499. doi:10.26355/eurrev-201811-16290

[91] Wang M, Li Y, Ni C, Song G. Honokiol attenuates Oligomeric amyloid β 1-42 -induced Alzheimer’s disease in mice through attenuating mitochondrial apoptosis and inhibiting the nuclear factor kappa-B signaling pathway. Cell Physiol Biochem. 2017;43(1):69-81.

[92] Voulgaropoulou SD, van Amelsvoort TAMJ, Prickaerts J, Vingerhoets C. The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies. Brain Res. 2019;1725:1725.

[93] Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK. Neuroprotective effects of quercetin in alzheimer’s disease. Biomol Ther. 2020;10(1):59.

[94] Tiwari SK, Agarwal S, Seth B, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano. 2014;8(1):76-103.

[95] Zhang X, Yin WK, Shi XD, Li Y. Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells. Eur J Pharm Sci. 2011;42(5):540-546.

[96] Hoppe JB, Coradini K, Frozza RL, et al. Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3β signaling pathway. Neurobiol Learn Mem. 2013;106:134-144.

[97] Huang HC, Xu K. Curcumin-mediated neuroprotection against amyloid-β-induced mitochondrial dysfunction involves the inhibition of GSK-3β. J Alzheimers Dis. 2012;32(4):981-996.

[98] Zhang X, Zhang H, Si L, Li Y. Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer’s disease. Pharmacol Rep. 2011;63(5):1101-1108.

[99] Abu-Elfotuh K, Tolba AMA, Hussein FH, et al. Anti-Alzheimer activity of combinations of cocoa with Vinpocetine or other nutraceuticals in rat model: modulation of Wnt3/β-catenin/GSK-3β/Nrf2/HO-1 and PERK/CHOP/Bcl-2 pathways. Pharmaceutics. 2023;15(8):2063.

[100] Palomera-Avalos V, Griñán-Ferré C, Puigoriol-Ilamola D, et al. Resveratrol protects SAMP8 brain under metabolic stress: focus on mitochondrial function and Wnt pathway. Mol Neurobiol. 2017;54(3):1661-1676.

[101] Xian YF, Ip SP, Mao QQ, Lin ZX. Neuroprotective effects of honokiol against beta-amyloid-induced neurotoxicity via GSK-3β and β-catenin signaling pathway in PC12 cells. Neurochem Int. 2016;97:8-14.

[102] Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009;11:11.

[103] De A. Wnt/Ca2+ signaling pathway: a brief overview. Acta Biochim Biophys Sin Shanghai. 2011;43(10):745-756.

[104] Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006;4(4):570-582.

[105] Zhang L, Yang X, Yang S, Zhang J. The Wnt/β-catenin signaling pathway in the adult neurogenesis. Eur J Neurosci. 2011;33(1):1-8.

[106] Caricasole A, Copani A, Caraci F, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer’s brain. J Neurosci. 2004;24(26):6021-6027.

[107] Kriks S, Shim JW, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature. 2011;480(7378):547-551.

[108] L’Episcopo F, Tirolo C, Testa N, et al. Plasticity of subventricular zone neuroprogenitors in MPTP (1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine) mouse model of Parkinson’S disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for neuropr. J Neurosci. 2012;32(6):2062-2085.

[109] L’Episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated Frizzled-1/β-catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener. 2011;6(1):49.

[110] Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson’s disease. Prog Neurobiol. 2005;77(1–2):128-138.

[111] Sleiman PMA, Healy DG, Muqit MMK, et al. Characterisation of a novel NR4A2 mutation in Parkinson’s disease brain. Neurosci Lett. 2009;457(2):75-79.

[112] Kwok JBJ, Hallupp M, Loy CT, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson’s disease. Ann Neurol. 2005;58(6):829-839.

[113] Bhat A, Mahalakshmi AM, Ray B, et al. Benefits of curcumin in brain disorders. Biofactors. 2019;45(5):666-689.

[114] Mursaleen L, Somavarapu S, Zariwala MG. Deferoxamine and curcumin loaded Nanocarriers protect against rotenone-induced neurotoxicity. J Parkinsons Dis. 2020;10(1):99-111.

[115] Wang YL, Ju B, Zhang YZ, et al. Protective effect of curcumin against oxidative stress-induced injury in rats with Parkinson’s disease through the Wnt/β-catenin signaling pathway. Cell Physiol Biochem. 2017;43(6):2226-2241.

[116] Dong Y, Wang Z, Yan Z, Wu C, Yang T, Qiu H. Neuroprotective effects of resveratrol on a mouse model of Parkinson’s disease via the Wnt/Beta-catenin signaling pathway. Indian J Pharm Sci. 2022;84(4):959-968.

[117] Haleagrahara N, Siew CJ, Ponnusamy K. Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats. J Toxicol Sci. 2013;38(1):25-33.

[118] Meng W, Jiang Y, Ma J. Is the prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis. Cancer Manag Res. 2017;9:411-425.

[119] Ge JF, Xu YY, Qin G, Cheng JQ, Chen FH. Resveratrol ameliorates the anxiety-and depression-like behavior of subclinical hypothyroidism rat: possible involvement of the HPT axis, HPA axis, and Wnt/β-catenin pathway. Front Endocrinol (Lausanne). 2016;7:44.

[120] Predes D, Maia LA, Matias I, et al. The Flavonol Quercitrin hinders GSK3 activity and potentiates the Wnt/β-catenin signaling pathway. Int J Mol Sci. 2022;23(20):12078.

[121] Suresh S, Vellapandian C. Cyanidin ameliorates Bisphenol A-induced Alzheimer’s disease pathology by restoring Wnt/β-catenin signaling Cascade: an in vitro study. Mol Neurobiol. 2024;61(4):2064-2080.

[122] Gong EJ, Park HR, Kim ME, et al. Morin attenuates tau hyperphosphorylation by inhibiting GSK3β. Neurobiol Dis. 2011;44(2):223-230.

[123] Yao Y, Gao Z, Liang W, et al. Osthole promotes neuronal differentiation and inhibits apoptosis via Wnt/β-catenin signaling in an Alzheimer’s disease model. Toxicol Appl Pharmacol. 2015;289(3):474-481.

[124] Shu T, Liu C, Pang M, et al. Salvianolic acid B promotes neural differentiation of induced pluripotent stem cells via PI3K/AKT/GSK3β/β-catenin pathway. Neurosci Lett. 2018;671:154-160.

[125] Alsadat AM, Nikbakht F, Hossein Nia H, et al. GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25–35 in a rat model of Alzheimer’s disease. Neuropeptides. 2021;90:102200.

[126] Tiwari SK, Agarwal S, Tripathi A, Chaturvedi RK. Bisphenol-A mediated inhibition of hippocampal neurogenesis attenuated by curcumin via canonical Wnt pathway. Mol Neurobiol. 2016;53(5):3010-3029.

[127] Anusha C, Sumathi T, Joseph LD. Protective role of apigenin on rotenone induced rat model of Parkinson’s disease: suppression of neuroinflammation and oxidative stress mediated apoptosis. Chem Biol Interact. 2017;269:67-79.

[128] Zamin LL, Dillenburg-Pilla P, Argenta-Comiran R, et al. Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of PI3-K pathway. Neurobiol Dis. 2006;24(1):170-182.

[129] Khamchai S, Chumboatong W, Hata J, Tocharus C, Suksamrarn A, Tocharus J. Morin attenuated cerebral ischemia/reperfusion injury through promoting angiogenesis mediated by Angiopoietin-1-Tie-2 Axis and Wnt/β-catenin pathway. Neurotox Res. 2022;40(1):14-25.

[130] Jin Z, Ke J, Guo P, Wang Y, Wu H. Quercetin improves blood-brain barrier dysfunction in rats with cerebral ischemia reperfusion via Wnt signaling pathway. Am J Transl Res. 2019;11(8):4683-4695.

[131] Zhang S, Jiao H. Kaempferol regulates apoptosis and migration of neural stem cells to attenuate cerebral infarction by O-GlcNAcylation of β-catenin. Open Life Sci. 2024;19(1):20220829.

[132] Xiao Y, Guan T, Yang X, et al. Baicalin facilitates remyelination and suppresses neuroinflammation in rats with chronic cerebral hypoperfusion by activating Wnt/β-catenin and inhibiting NF-κB signaling. Behav Brain Res. 2023;442:442.

[133] Xie Y, Zhang J, Lin Y, et al. Aberrant development corrected in adult-onset Huntington’s disease iPSC-derived neuronal cultures via WNT signaling modulation. Stem Cell Reports. 2020;14:406-419.

[134] Sandhir R, Mehrotra A. Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington’s disease. Biochim Biophys Acta Mol basis Dis. 2013;1832(3):421-430.

[135] Hsu CH, Cheng AL. The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Med Biol. 2007;595:471-480.

[136] Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuro Ophthalmol. 2010;30(4):328-339.

[137] Jugait S, Areti A, Nellaiappan K, et al. Neuroprotective effect of Baicalein against Oxaliplatin-induced peripheral neuropathy: impact on oxidative stress, neuro-inflammation and WNT/β-catenin signaling. Mol Neurobiol. 2022;59(7):4334-4350.

[138] Markert CD, Kim E, Gifondorwa DJ, Childers MK, Milligan CE. A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food. 2010;13(5):1081-1085.

[139] Menet R, Lecordier S, ElAli A. Wnt pathway: an emerging player in vascular and traumatic mediated brain injuries. Front Physiol. 2020;11:11.

[140] Page S, Al-Ahmad A. Determining the effect of the WNT/b-catenin pathway on the ischemic blood-brain barrier using induced pluripotent stem cells. FASEB J. 2018;32:32(S1).

[141] Patel MI, Gupta A, Dey CS. Potentiation of neuronal insulin signaling and glucose uptake by resveratrol: the involvement of AMPK. Pharmacol Rep. 2011;63(5):1162-1168.

[142] Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways. Eur J Neurosci. 2012;36(7):2899-2905.

[143] Frozza RL, Bernardi A, Hoppe JB, et al. Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Mol Neurobiol. 2013;47(3):1066-1080.

[144] Varamini B, Sikalidis AK, Bradford KL. Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study. Int J Food Sci Nutr. 2014;65(1):89-96.

[145] Abdel-Aleem GA, Khaleel EF, Mostafa DG, Elberier LK. Neuroprotective effect of resveratrol against brain ischemia reperfusion injury in rats entails reduction of DJ-1 protein expression and activation of PI3K/Akt/GSK3b survival pathway. Arch Physiol Biochem. 2016;122(4):200-213.

[146] Oh S, Gwak J, Park S, Yang CS. Green tea polyphenol EGCG suppresses Wnt/β-catenin signaling by promoting GSK-3β-and PP2A-independent β-catenin phosphorylation/degradation. Biofactors. 2014;40(6):586-595.

[147] Rai SN, Singh BK, Rathore AS, et al. Quality control in Huntington’s disease: a therapeutic target. Neurotox Res. 2019;36(3):612-626.

[148] Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington’s disease: an updated systematic review and meta-analysis. Mov Disord. 2022;37(12):2327-2335.

[149] Starkstein SE, Brandt J, Bylsma F, Peyser C, Folstein M, Folstein SE. Neuropsychological correlates of brain atrophy in Huntington’s disease: a magnetic resonance imaging study. Neuroradiology. 1992;34(6):487-489.

[150] Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(4):219-226.

[151] Mason SL, Barker RA. Advancing pharmacotherapy for treating Huntingtons disease: A review of the existing literature. Expert Opin Pharmacother. 2016;17(1):41-52.

[152] Ghatak S, Raha S. Micro RNA-214 contributes to proteasome independent downregulation of beta catenin in Huntington’s disease knock-in striatal cell model STHdhQ111/Q111. Biochem Biophys Res Commun. 2015;459(3):509-514.

[153] Liu T, Im W, Mook-Jung I, Kim M. MicroRNA-124 slows down the progression of huntington’s disease by promoting neurogenesis in the striatum. Neural Regen Res. 2015;10(5):786-791.

[154] Lim RG, Quan C, Reyes-Ortiz AM, et al. Huntington’s disease iPSC-derived brain microvascular endothelial cells reveal WNT-mediated Angiogenic and blood-brain barrier deficits. Cell Rep. 2017;19(7):1365-1377.

[155] McLeod JG. Multiple sclerosis–A review. Aust NZ J Med. 1982;12(4):302-308.

[156] Balasa R, Barcutean L, Balasa A, Motataianu A, Roman-Filip C, Manu D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Hum Immunol. 2020;81(5):237-243.

[157] Suryawanshi A, Manoharan I, Hong Y, et al. Canonical Wnt signaling in dendritic cells regulates Th1/Th17 responses and suppresses autoimmune neuroinflammation. J Immunol. 2015;194(7):3295-3304.

[158] Fancy SPJ, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 2009;23(13):1571-1585.

[159] Xie C, Li Z, Zhang GX, Guan Y. Wnt signaling in remyelination in multiple sclerosis: friend or foe? Mol Neurobiol. 2014;49(3):1117-1125.

[160] Ortiz GG, Pacheco-Moisés FP, Macías-Islas MÁ, et al. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014;45(8):687-697.

[161] Tran KA, Zhang X, Predescu D, et al. Endothelial β-catenin signaling is required for maintaining adult blood-brain barrier integrity and central nervous system homeostasis. Circulation. 2016;133(2):177-186.

[162] Kernich CA. Amyotrophic lateral sclerosis. Neurologist. 2000;6(4):243-244.

[163] Pehar M, Harlan BA, Killoy KM, Vargas MR. Role and therapeutic potential of astrocytes in amyotrophic lateral sclerosis. Curr Pharm Des. 2018;23(33):5010-5021.

[164] Inestrosa NC, Varela-Nallar L. Wnt signalling in neuronal differentiation and development. Cell Tissue Res. 2015;359(1):215-223.

[165] González-Fernández C, Mancuso R, Del Valle J, Navarro X, Rodríguez FJ. Wnt signaling alteration in the spinal cord of amyotrophic lateral sclerosis transgenic mice: special focus on Frizzled-5 cellular expression pattern. PLoS One. 2016;11(5):e0155867.

[166] Yu L, Guan Y, Wu X, et al. Wnt signaling is altered by spinal cord neuronal dysfunction in amyotrophic lateral sclerosis transgenic mice. Neurochem Res. 2013;38(9):1904-1913.

[167] Yang W, Leystra-Lantz C, Strong MJ. Upregulation of GSK3β expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Res. 2008;1196:131-139.

[168] Nonneman A, Robberecht W, Van Den Bosch L. The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. Neurodegener Dis Manag. 2014;4(3):223-239.

[169] Verma S, Khurana S, Vats A, et al. Neuromuscular junction dysfunction in amyotrophic lateral sclerosis. Mol Neurobiol. 2022;59(3):1502-1527.

[170] Serafino A, Giovannini D, Rossi S, Cozzolino M. Targeting the Wnt/β-catenin pathway in neurodegenerative diseases: recent approaches and current challenges. Expert Opin Drug Discov. 2020;15(7):803-822.

[171] Marchetti B, Tirolo C, L’Episcopo F, et al. Parkinson’s disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair. Aging Cell. 2020;19(3):e13101.

[172] AH L. Wnt/β-catenin and its diverse physiological cell signaling pathways in neurodegenerative and neuropsychiatric disorders. J Neuroimmune Pharmacol. 2012;7(4):725-730.

[173] Xiao J. Phytochemicals in medicine and food. Phytochem Rev. 2015;14(3):317-320.

[174] Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3):regulation, actions, and diseases. Pharmacol Ther. 2015;148:114-131.

[175] Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun. 2005;328(1):227-234.

[176] Tao Q, Yokota C, Puck H, et al. Maternal Wnt11 activates the canonical Wnt signaling pathway required for axis formation in Xenopus embryos. Cell. 2005;120(6):857-871.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.